A shareholder class action against software company Nuix will go ahead as planned, after a stay application threatened to put the proceeding on ice pending the outcome of a separate case brought by ASIC.
Bayer told a jury that clinical trials from the 1990’s to 2014 showed its Essure birth control device was “safe and efficacious”, as the pharmaceutical giant faces trial in a class action by patients who claim they suffered debilitating injuries from the device.
Pharmaceutical giant Bayer cannot write off debilitating chronic pain and bleeding which patients allegedly experienced after being implanted with Essure contraceptives as “common women’s symptoms”, a court has heard in the first day of trial in a long-running class action.
A judge has indicated his willingness to approve a $25 million settlement in a class action against dairy co-op Fonterra, but deferred the question of the funder’s cut until after the Full Court rules on whether the court has the power to make a common fund order at settlement.
A former Nuix director has made a bid to stay a shareholder class action, which accuses the software company of failing to alert the market to red flags in the business, pending the outcome of separate proceedings by ASIC.
Class action settlement sums reached new highs last year, with the ten largest agreements totalling almost $1 billion, almost half of which was secured by one plaintiff law firm.
A judge has cut a funder’s commission by 33 per cent after approving a $20 million settlement in a sham contracting class action against telco contractor BSA Limited, finding that funders should receive “significantly lower” payouts in employment cases.
A judge has approved a $33 million settlement in a class action against vocational education provider Box Hill Institute, but taken the ax to a law firm’s proposed 18.25 per cent loading on its fees, saying courts shouldn’t approve uplifts for run of the mill legal work.
Nuix has pointed the finger at its accountant PricewaterhouseCoopers in the software company’s defence to a class action over a prospectus for its $1.8 billion IPO two years ago.
A class action against Bayer over its allegedly defective Essure contraceptive devices has admonished the drug manufacturer’s bid to shield emails considered privileged in similar US litigation, arguing “thoughts and prayers” are needed to sustain the claim.